El-Galaly, Tarec Christoffer1; Mylam, Karen Juul8; Bøgsted, Martin2; Brown, Peter8; Rossing, Maria8; Gang, Anne Ortved8; Haglund, Anne1; Arboe, Bente8; Clausen, Michael Roost8; Jensen, Paw4; Pedersen, Michael8; Bukh, Anne8; Jensen, Bo Amdi8; Poulsen, Christian Bjørn8; d'Amore, Francesco8; Hutchings, Martin9
1 The Faculty of Medicine, Aalborg University, VBN2 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN3 Klinik Medicin, The Faculty of Medicine, Aalborg University, VBN4 Blodsygdomme (Hæmatologi), The Faculty of Medicine, Aalborg University, VBN5 Forskningsadministrationen, Aalborg Universitetshospital, The Faculty of Medicine, Aalborg University, VBN6 The Faculty of Engineering and Science, Aalborg University, VBN7 Department of Mathematical Sciences, The Faculty of Engineering and Science, Aalborg University, VBN8 unknown9 Institut for Klinisk Medicin
A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma
After first-line therapy, patients with Hodgkin and aggressive non-Hodgkin lymphomas are followed closely for early signs of relapse. The current follow-up practice with frequent use of surveillance imaging is highly controversial and warrants a critical evaluation. Therefore a retrospective multicenter study of relapsed Hodgkin and aggressive non-Hodgkin lymphomas (nodal T-cell and diffuse large B-cell lymphomas) was conducted. All included patients had been diagnosed during the period 2002-2011 and relapsed after achieving complete remission on first-line therapy. Characteristics and outcome of imaging-detected relapses were compared to other relapses. A total of 258 patients with recurrent lymphoma were included in the study. Relapse investigations were initiated outside preplanned visits in 52% of the patients. Relapse detection could be attributed to patient-reported symptoms alone or in combination with abnormal blood tests or physical examination in 64% of the patients. Routine imaging prompted relapse investigations in 27% of the patients. The estimated number of routine scans per relapse was 91-255 depending on the lymphoma subtype. Patients with imaging-detected relapse had lower disease burden (P=.045) and reduced risk of death following relapse (hazard ratio 0.62, P=.02 in multivariate analysis). Patient reported symptoms are still the most common factor for detecting lymphoma relapse and the high number of scans per relapse calls for improved criteria for use of surveillance imaging. However, imaging-detected relapse was associated with lower disease burden and a possible survival advantage. The future role of routine surveillance imaging should be defined in a randomized trial.
American Journal of Hematology, 2014, Vol 89, Issue 6, p. 575-580